ArticleeLife2017
Exploiting CRISPR-Cas to manipulate
Article in eLife, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 65 citations in OpenAlex.
- CRISPR1-mediated virulence and erythromycin resistance stabilization drives regional dominance ofFrontiers in cellular and infection microbiology · 2026Article
- Molecular Profiling of CRISPR-Cas System, Virulence Traits, and Antimicrobial Resistance inInternational journal of microbiology · 2026Article
- Avian PathogenicVeterinary sciences · 2025Review
- Hidden diversity inMicrobiology spectrum · 2025Article
- Reinvigorating AMR resilience: leveraging CRISPR-Cas technology potentials to combat the 2024 WHO bacterial priority pathogens for enhanced global health security-a systematic review.Tropical medicine and health · 2025Review
- CRISPR-Cas systems in enterococci.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- Prevalence of the CRISPR-cas system and its association with antibiotic resistance in clinical Klebsiella pneumoniae isolates.BMC infectious diseases · 2024Article
- CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Blunted blades: new CRISPR-derived technologies to dissect microbial multi-drug resistance and biofilm formation.mSphere · 2024Review
- Enterococcus faecalis Strains with Compromised CRISPR-Cas Defense Emerge under Antibiotic Selection for a CRISPR-Targeted Plasmid.Applied and environmental microbiology · 2023Article
- CRISPR-Based Gene Editing inPharmaceuticals (Basel, Switzerland) · 2023Review
- Analysis of genetic structure and function of clustered regularly interspaced short palindromic repeats loci in 110Frontiers in microbiology · 2023Article
- Vancomycin Resistance inMicroorganisms · 2022Review
- Early life microbiota transplantation from highly feed-efficient broiler improved weight gain by reshaping the gut microbiota in laying chicken.Frontiers in microbiology · 2022Article
- The Application of the CRISPR-Cas System in Antibiotic Resistance.Infection and drug resistance · 2022Review
- Association of CRISPR-Cas System with the Antibiotic Resistance and Virulence Genes in Nosocomial Isolates ofInfection and drug resistance · 2022Article
- Superior Conjugative Plasmids Delivered by Bacteria to Diverse Fungi.Biodesign research · 2022Article
- Let Me Upgrade You: Impact of Mobile Genetic Elements on Enterococcal Adaptation and Evolution.Journal of bacteriology · 2021Review
- Role of CRISPR-Cas system on antibiotic resistance patterns of Enterococcus faecalis.Annals of clinical microbiology and antimicrobials · 2021Article
- CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies.Antibiotics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
CRISPR-Cas provides a barrier to horizontal gene transfer in prokaryotes. It was previously observed that functional CRISPR-Cas systems are absent from multidrug-resistant (MDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.